MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.140
+0.140
+3.50%
After Hours: 4.200 +0.06 +1.45% 18:32 05/20 EDT
OPEN
4.070
PREV CLOSE
4.000
HIGH
4.180
LOW
3.980
VOLUME
3.97M
TURNOVER
0
52 WEEK HIGH
12.83
52 WEEK LOW
3.480
MARKET CAP
607.29M
P/E (TTM)
-3.4113
1D
5D
1M
3M
1Y
5Y
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analysts Are Reducing Their Forecasts For This Year
Market forces rained on the parade of Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders today, when the analysts...
Simply Wall St. · 05/08 12:09
Sangamo Therapeutics stock slips despite Q1 revenue beat
Sangamo Therapeutics (NASDAQ:SGMO) stock fell May 6 despite its Q1 results beat analysts' estimates a day ago. Q1 revenue rose +7.41% Y/Y to $28.23M. The company said the increase was
Seekingalpha · 05/06 15:02
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 6.25% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:45
Sangamo Therapeutics Q1 EPS $(0.30) Beats $(0.31) Estimate, Sales $28.23M Beat $27.29M Estimate
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 6.25 percent increase over losses of $(0.32) per share
Benzinga · 05/05 20:53
Sangamo Therapeutics GAAP EPS of -$0.30 beats by $0.01, revenue of $28.23M beats by $0.94M
Sangamo Therapeutics press release (NASDAQ:SGMO): Q1 GAAP EPS of -$0.30 beats by $0.01. Revenue of $28.23M (+7.4% Y/Y) beats by $0.94M. Cash, cash equivalents and marketable securities as of March
Seekingalpha · 05/05 20:06
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 35.82% and 33.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:35
Sangamo Therapeutics's Earnings: A Preview
Sangamo Therapeutics (NASDAQ:SGMO) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Sangamo Therapeutics will report an earnings per share (EPS) ...
Benzinga · 05/04 21:19
More
No Data
Learn about the latest financial forecast of SGMO. Analyze the recent business situations of Sangamo Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

18.18%Strong Buy
54.55%Buy
27.27%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SGMO stock price target is 16.04 with a high estimate of 25.00 and a low estimate of 4.400.
High25.00
Average16.04
Low4.400
Current 4.140
EPS
Actual
Estimate
-0.28-0.21-0.14-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 292
Institutional Holdings: 86.33M
% Owned: 58.86%
Shares Outstanding: 146.69M
TypeInstitutionsShares
Increased
59
6.43M
New
29
1.09M
Decreased
59
3.68M
Sold Out
28
1.25M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
H. Stewart Parker
President/Chief Executive Officer/Director
Alexander Macrae
Chief Financial Officer/Senior Vice President
Prathyusha Duraibabu
Chief Operating Officer/Executive Vice President
D. Mark McClung
Executive Vice President
R. Andrew Ramelmeier
Senior Vice President/Chief Scientific Officer
Jason Fontenot
Senior Vice President/General Counsel/Secretary
Scott Willoughby
Senior Vice President
Robert Schott
Independent Director
Robert Carey
Independent Director
Kenneth Hillan
Independent Director
John Markels
Independent Director
James Meyers
Independent Director
Saira Ramasastry
Independent Director
Karen Smith
No Data
No Data
About SGMO
Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.

Webull offers kinds of Sangamo Therapeutics Inc stock information, including NASDAQ:SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.